<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02574520</url>
  </required_header>
  <id_info>
    <org_study_id>C803-028</org_study_id>
    <nct_id>NCT02574520</nct_id>
  </id_info>
  <brief_title>Trial of Extended Release Bupivacaine for Pain Relief After Surgery</brief_title>
  <acronym>PERSIST</acronym>
  <official_title>A Placebo-controlled (Part 1) or Active-controlled (Part 2) Trial of SABER® -Bupivacaine for the Management of Postoperative Pain Following Laparoscopic Cholecystectomy (PERSIST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Durect</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Durect</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study of SABER® -Bupivacaine, an experimental medication designed to&#xD;
      reduce pain for up to 3 days after surgery. Given once by the surgeon at the end of surgery,&#xD;
      SABER® - Bupivacaine delivers a locally-acting pain reliever directly to the surgical wound.&#xD;
&#xD;
      The purpose of this study is to measure how well it works in reducing pain after laparoscopic&#xD;
      cholecystectomy (surgery to remove the gall bladder) and to investigate the safety of&#xD;
      SABER®-Bupivacaine (its side effects).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity on Movement From 0-48 Hours Post-Treatment</measure>
    <time_frame>Assessed from 0 to 48 hours post-dose, summary measure (see description) reported.</time_frame>
    <description>A derived measure computed based on a patient-reported numerical pain rating scale assessing pain as a whole number from 0 (no pain) to 10 (worst pain imaginable) when the subject sits up from a supine position. This measure was evaluated by electronic diary at 13 planned time points from 0 to 48 hours post-treatment. The values reported are mean pain scores for each treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Using the NPRS-11 With Movement</measure>
    <time_frame>Assessed from 0 to 72 hours post-dose, summary measure (see description) reported.</time_frame>
    <description>A derived measure computed based on a patient-reported numerical pain rating scale assessing pain as a whole number from 0 (no pain) to 10 (worst pain imaginable) when the subject sits up from a supine position. This measure was evaluated by electronic diary at 17 planned time points from 0 to 72 hours post-treatment. The values reported are mean pain scores for each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total IV Morphine-equivalent Dose of Rescue Opioids</measure>
    <time_frame>0-72 hrs. post dose (after surgery)</time_frame>
    <description>IV morphine-equivalent dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Silverman's Integrated Analgesic (SIA) Assessment Score</measure>
    <time_frame>0 to 72 hours</time_frame>
    <description>Score of Integrated Analgesia (SIA) is a composite endpoint that integrates pain assessment scores with opioid use over various collections of timepoints by ranking the pain score and the opioid use separately across treatments. After the scores are computed the means are calculated across time points to provide a single overall treatment effect. The composite SIA score ranges from -200 to 200 with -200 being the best case and 200 the worst case.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Not Taking Rescue Medication From PACU Discharge to 72 Hours</measure>
    <time_frame>From PACU Discharge to 72 Hours post-treatment</time_frame>
    <description>Pooled SABER-Bupivacaine parts 1 + 2 vs. Bupivacaine HCl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Opioid Rescue Medication Use After Discharge From the PACU</measure>
    <time_frame>From PACU Discharge to 72 Hours post-treatment</time_frame>
    <description>Pooled SABER-Bupivacaine parts 1 + 2 vs. Bupivacaine HCl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PACU Discharge Eligibility as Assessed by Modified Post-Anesthesia Discharge Scoring System (mPADSS)</measure>
    <time_frame>From admission to discharge from PACU (Approximately 0 to 12 hours)</time_frame>
    <description>mPADSS is a tool used to determine eligibility for discharge from the PACU after ambulatory surgery. It includes an assessment of parameters such as vital signs, activity level, nausea/vomiting, pain, and surgical bleeding. For this trial, evaluation of eligibility for PACU discharge by mPADSS has been slightly modified to provide a standardized means of assessing eligibility for PACU discharge across multiple investigative sites and also ensures that nonmedical complications, such as a missing ride home, do not interfere with evaluation of test drug effects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">399</enrollment>
  <condition>Post Operative Pain</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SABER-Bupivacaine and Saline Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SABER-Bupivacaine and Bupivacaine HCl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SABER-Bupivacaine (Part 1)</intervention_name>
    <description>5 ml once at end of surgery</description>
    <arm_group_label>Part 1</arm_group_label>
    <other_name>POSIMIR® bupivacaine solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SABER-Bupivacaine (Part 2)</intervention_name>
    <description>5 ml once at end of surgery</description>
    <arm_group_label>Part 2</arm_group_label>
    <other_name>POSIMIR® bupivacaine solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Placebo</intervention_name>
    <description>5 ml once at end of surgery</description>
    <arm_group_label>Part 1</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCl</intervention_name>
    <description>0.5%, 15 ml, once at end of surgery</description>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled for elective outpatient laparoscopic cholecystectomy using a&#xD;
             conventional 4-port laparoscopic procedure.&#xD;
&#xD;
          -  Must be able and willing to provide written informed consent, complete trial-related&#xD;
             procedures, and communicate with the trial staff.&#xD;
&#xD;
          -  Males and females 18 years of age or older.&#xD;
&#xD;
          -  ASA Class I, II, or III.&#xD;
&#xD;
          -  Patients of child-bearing potential must agree to use a medically acceptable method of&#xD;
             contraception to prevent pregnancy for the duration of their participation in the&#xD;
             trial.&#xD;
&#xD;
          -  Must be living close enough to the investigative site to attend the four scheduled&#xD;
             follow-up clinic visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing females.&#xD;
&#xD;
          -  Patients with absolute or relative contraindications to laparoscopic cholecystectomy.&#xD;
&#xD;
          -  Patients with prior midline abdominal surgery who are at risk for adhesions that may&#xD;
             complicate laparoscopic cholecystectomy and/or accurate pain assessments.&#xD;
&#xD;
          -  Patients requiring emergency surgery or urgent surgery (fewer than 5 days between&#xD;
             screening and surgery).&#xD;
&#xD;
          -  Patients with a pre-planned overnight stay or pre-planned hospital admission.&#xD;
&#xD;
          -  Patients scheduled for single incision, mini trocars, natural orifice transluminal&#xD;
             endoscopic surgery (NOTES), robotic laparoscopic procedures, or any procedure (other&#xD;
             than cholangiograms and minimal adhesiolysis) in addition to laparoscopic&#xD;
             cholecystectomy.&#xD;
&#xD;
          -  Patients with known hypersensitivity to amide local anesthetics such as bupivacaine.&#xD;
&#xD;
          -  Patients with acute pain that is not due to cholecystitis.&#xD;
&#xD;
          -  Patients with a history of chronic pain unrelated to gallbladder disease.&#xD;
&#xD;
          -  Patients with ongoing depression or psychosis.&#xD;
&#xD;
          -  Patients undergoing long-term treatment with opioids or other analgesics, including&#xD;
             acetaminophen, NSAIDs, anticonvulsants (gabapentin or pregabalin), and antidepressants&#xD;
             (SSRIs, SNRIs, and tricyclics), but not including daily low-dose aspirin.&#xD;
&#xD;
          -  Patients who are being treated chronically with systemic corticosteroids or who will&#xD;
             require peri-operative corticosteroids because of adrenal insufficiency (inhalational&#xD;
             or topical corticosteroids are permitted).&#xD;
&#xD;
          -  Patients who may be unsuitable for opioid administration (such as sensitivity [e.g.,&#xD;
             history of severe nausea and vomiting] hypersensitivity, known history of abuse or&#xD;
             addiction, or unwillingness to take prescribed rescue opioids).&#xD;
&#xD;
          -  Use of anticoagulants and antiplatelet drugs (with exception of low dose aspirin) in&#xD;
             the 1 week prior to surgery.&#xD;
&#xD;
          -  Patients who are incapable of operating the electronic diary.&#xD;
&#xD;
          -  Patients participating in any other trial with an investigational drug or device&#xD;
             concurrently or less than 30 days prior to surgery for this trial.&#xD;
&#xD;
          -  Patients who, in the Investigator's opinion, should not participate in the trial or&#xD;
             may not be capable of following the trial procedures for any reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dave Ellis, MD</last_name>
    <role>Study Director</role>
    <affiliation>Durect</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Durect Study Site 04</name>
      <address>
        <city>Florence</city>
        <state>Alabama</state>
        <zip>35360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 03</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site 24</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 15</name>
      <address>
        <city>Fontana</city>
        <state>California</state>
        <zip>92335</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 02</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 18</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 22</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 12</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 21</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 17</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 16</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 20</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 05</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 13</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 09</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 11</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 07</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 14</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 08</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site 01</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durect Study Site 23</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 9, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2015</study_first_posted>
  <results_first_submitted>March 3, 2021</results_first_submitted>
  <results_first_submitted_qc>June 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2021</results_first_posted>
  <disposition_first_submitted>May 23, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>May 23, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 25, 2018</disposition_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-operative pain</keyword>
  <keyword>non-opioid analgesic</keyword>
  <keyword>opioid reduction</keyword>
  <keyword>laparoscopic cholecystectomy</keyword>
  <keyword>laparoscopic surgery</keyword>
  <keyword>bupivacaine</keyword>
  <keyword>extended release</keyword>
  <keyword>locally acting analgesic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02574520/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 22 sites in the US. First subject was randomized on 17 November 2015. Study completion date was on 16 Aug 2017.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>SABER-Bupivacaine (Part 1)</title>
          <description>5 ml once at end of surgery</description>
        </group>
        <group group_id="P2">
          <title>Saline Placebo (Part 1)</title>
          <description>5 ml once at end of surgery</description>
        </group>
        <group group_id="P3">
          <title>SABER-Bupivacaine (Part 2)</title>
          <description>5 ml once at end of surgery</description>
        </group>
        <group group_id="P4">
          <title>Bupivacaine HCL (Part 2)</title>
          <description>0.5%, 15 ml, once at end of surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="153"/>
                <participants group_id="P4" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dosed</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="148"/>
                <participants group_id="P4" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="148"/>
                <participants group_id="P4" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not dosed</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Enrolled Subjects (ITT population)</population>
      <group_list>
        <group group_id="B1">
          <title>SABER-Bupivacaine (Part 1)</title>
          <description>5 ml once at end of surgery</description>
        </group>
        <group group_id="B2">
          <title>Saline Placebo (Part 1)</title>
          <description>5 ml once at end of surgery</description>
        </group>
        <group group_id="B3">
          <title>SABER-Bupivacaine (Part 2)</title>
          <description>5 ml once at end of surgery</description>
        </group>
        <group group_id="B4">
          <title>Bupivacaine HCL (Part 2)</title>
          <description>0.5%, 15 ml, once at end of surgery</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="153"/>
            <count group_id="B4" value="152"/>
            <count group_id="B5" value="399"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.0" spread="14.2"/>
                    <measurement group_id="B2" value="41.8" spread="12.8"/>
                    <measurement group_id="B3" value="45.5" spread="13.5"/>
                    <measurement group_id="B4" value="44.7" spread="13.9"/>
                    <measurement group_id="B5" value="44.8" spread="13.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="117"/>
                    <measurement group_id="B5" value="292"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="141"/>
                    <measurement group_id="B4" value="135"/>
                    <measurement group_id="B5" value="355"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="153"/>
                    <measurement group_id="B4" value="152"/>
                    <measurement group_id="B5" value="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity on Movement From 0-48 Hours Post-Treatment</title>
        <description>A derived measure computed based on a patient-reported numerical pain rating scale assessing pain as a whole number from 0 (no pain) to 10 (worst pain imaginable) when the subject sits up from a supine position. This measure was evaluated by electronic diary at 13 planned time points from 0 to 48 hours post-treatment. The values reported are mean pain scores for each treatment group.</description>
        <time_frame>Assessed from 0 to 48 hours post-dose, summary measure (see description) reported.</time_frame>
        <population>mITT Population, results for only the prespecified analysis population {SABER-Bupivacaine (Part 2) and Bupivacaine HCl (Part 2)} are provided, there was no prespecified primary outcome measure that included the SABER-Bupivacaine (Part 1) arm or the Saline Placebo (Part 1) arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2/SABER-Bupivacaine</title>
            <description>5 ml once at end of surgery</description>
          </group>
          <group group_id="O2">
            <title>Part 2/Bupivacaine HCl</title>
            <description>0.5%, 15 ml, once at end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity on Movement From 0-48 Hours Post-Treatment</title>
          <description>A derived measure computed based on a patient-reported numerical pain rating scale assessing pain as a whole number from 0 (no pain) to 10 (worst pain imaginable) when the subject sits up from a supine position. This measure was evaluated by electronic diary at 13 planned time points from 0 to 48 hours post-treatment. The values reported are mean pain scores for each treatment group.</description>
          <population>mITT Population, results for only the prespecified analysis population {SABER-Bupivacaine (Part 2) and Bupivacaine HCl (Part 2)} are provided, there was no prespecified primary outcome measure that included the SABER-Bupivacaine (Part 1) arm or the Saline Placebo (Part 1) arm.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.55" spread="0.065"/>
                    <measurement group_id="O2" value="5.87" spread="0.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pain Intensity on Movement 0-48 hr</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Primary</non_inferiority_desc>
            <p_value>0.124</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model with repeated measures (MMRM) for scheduled pain measurements was estimated with time as a repeating factor within subject.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
            <estimate_desc>Least squares mean from the MMRM described in the Statistical Test of Hypothesis.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Using the NPRS-11 With Movement</title>
        <description>A derived measure computed based on a patient-reported numerical pain rating scale assessing pain as a whole number from 0 (no pain) to 10 (worst pain imaginable) when the subject sits up from a supine position. This measure was evaluated by electronic diary at 17 planned time points from 0 to 72 hours post-treatment. The values reported are mean pain scores for each treatment group.</description>
        <time_frame>Assessed from 0 to 72 hours post-dose, summary measure (see description) reported.</time_frame>
        <population>mITT Population, results for only the prespecified analysis population {SABER-Bupivacaine (Part 1 and Part 2 combined) and Bupivacaine HCl (Part 2)} are provided, there was no prespecified secondary outcome measure that included the Saline Placebo (Part 1) arm or the SABER-Bupivacaine (Part 1) arm as a standalone treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 and Part 2: SABER-Bupivacaine</title>
            <description>5 ml once at end of surgery</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Bupivacaine HCl</title>
            <description>0.5%, 15 ml, once at end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Using the NPRS-11 With Movement</title>
          <description>A derived measure computed based on a patient-reported numerical pain rating scale assessing pain as a whole number from 0 (no pain) to 10 (worst pain imaginable) when the subject sits up from a supine position. This measure was evaluated by electronic diary at 17 planned time points from 0 to 72 hours post-treatment. The values reported are mean pain scores for each treatment group.</description>
          <population>mITT Population, results for only the prespecified analysis population {SABER-Bupivacaine (Part 1 and Part 2 combined) and Bupivacaine HCl (Part 2)} are provided, there was no prespecified secondary outcome measure that included the Saline Placebo (Part 1) arm or the SABER-Bupivacaine (Part 1) arm as a standalone treatment group.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.94" spread="0.049"/>
                    <measurement group_id="O2" value="5.40" spread="0.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total IV Morphine-equivalent Dose of Rescue Opioids</title>
        <description>IV morphine-equivalent dose</description>
        <time_frame>0-72 hrs. post dose (after surgery)</time_frame>
        <population>mITT Population, results for only the prespecified analysis population {SABER-Bupivacaine (Part 1 and Part 2 combined) and Bupivacaine HCl (Part 2)} are provided, there was no prespecified secondary outcome measure that included the Saline Placebo (Part 1) arm or the SABER-Bupivacaine (Part 1) arm as a standalone treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 and Part 2: SABER-Bupivacaine</title>
            <description>5 ml once at end of surgery</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Bupivacaine HCl</title>
            <description>0.5%, 15 ml, once at end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Total IV Morphine-equivalent Dose of Rescue Opioids</title>
          <description>IV morphine-equivalent dose</description>
          <population>mITT Population, results for only the prespecified analysis population {SABER-Bupivacaine (Part 1 and Part 2 combined) and Bupivacaine HCl (Part 2)} are provided, there was no prespecified secondary outcome measure that included the Saline Placebo (Part 1) arm or the SABER-Bupivacaine (Part 1) arm as a standalone treatment group.</population>
          <units>IV morphine equivalent (mg)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" spread="1.37"/>
                    <measurement group_id="O2" value="22.6" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Silverman's Integrated Analgesic (SIA) Assessment Score</title>
        <description>Score of Integrated Analgesia (SIA) is a composite endpoint that integrates pain assessment scores with opioid use over various collections of timepoints by ranking the pain score and the opioid use separately across treatments. After the scores are computed the means are calculated across time points to provide a single overall treatment effect. The composite SIA score ranges from -200 to 200 with -200 being the best case and 200 the worst case.</description>
        <time_frame>0 to 72 hours</time_frame>
        <population>mITT Population, results for only the prespecified analysis population {SABER-Bupivacaine (Part 1 and Part 2 combined) and Bupivacaine HCl (Part 2)} are provided, there was no prespecified secondary outcome measure that included the Saline Placebo (Part 1) arm or the SABER-Bupivacaine (Part 1) arm as a standalone treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 and Part 2: SABER-Bupivacaine</title>
            <description>5 ml once at end of surgery</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Bupivacaine HCl</title>
            <description>0.5%, 15 ml, once at end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Silverman's Integrated Analgesic (SIA) Assessment Score</title>
          <description>Score of Integrated Analgesia (SIA) is a composite endpoint that integrates pain assessment scores with opioid use over various collections of timepoints by ranking the pain score and the opioid use separately across treatments. After the scores are computed the means are calculated across time points to provide a single overall treatment effect. The composite SIA score ranges from -200 to 200 with -200 being the best case and 200 the worst case.</description>
          <population>mITT Population, results for only the prespecified analysis population {SABER-Bupivacaine (Part 1 and Part 2 combined) and Bupivacaine HCl (Part 2)} are provided, there was no prespecified secondary outcome measure that included the Saline Placebo (Part 1) arm or the SABER-Bupivacaine (Part 1) arm as a standalone treatment group.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.3" spread="8.83"/>
                    <measurement group_id="O2" value="-1.5" spread="9.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Not Taking Rescue Medication From PACU Discharge to 72 Hours</title>
        <description>Pooled SABER-Bupivacaine parts 1 + 2 vs. Bupivacaine HCl</description>
        <time_frame>From PACU Discharge to 72 Hours post-treatment</time_frame>
        <population>mITT Population, results for only the prespecified analysis population {SABER-Bupivacaine (Part 1 and Part 2 combined) and Bupivacaine HCl (Part 2)} are provided, there was no prespecified secondary outcome measure that included the Saline Placebo (Part 1) arm or the SABER-Bupivacaine (Part 1) arm as a standalone treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 and Part 2: SABER-Bupivacaine</title>
            <description>5 ml once at end of surgery</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Bupivacaine HCl</title>
            <description>0.5%, 15 ml, once at end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Not Taking Rescue Medication From PACU Discharge to 72 Hours</title>
          <description>Pooled SABER-Bupivacaine parts 1 + 2 vs. Bupivacaine HCl</description>
          <population>mITT Population, results for only the prespecified analysis population {SABER-Bupivacaine (Part 1 and Part 2 combined) and Bupivacaine HCl (Part 2)} are provided, there was no prespecified secondary outcome measure that included the Saline Placebo (Part 1) arm or the SABER-Bupivacaine (Part 1) arm as a standalone treatment group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Opioid Rescue Medication Use After Discharge From the PACU</title>
        <description>Pooled SABER-Bupivacaine parts 1 + 2 vs. Bupivacaine HCl</description>
        <time_frame>From PACU Discharge to 72 Hours post-treatment</time_frame>
        <population>mITT Population, results for only the prespecified analysis population {SABER-Bupivacaine (Part 1 and Part 2 combined) and Bupivacaine HCl (Part 2)} are provided, there was no prespecified secondary outcome measure that included the Saline Placebo (Part 1) arm or the SABER-Bupivacaine (Part 1) arm as a standalone treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 and Part 2: SABER-Bupivacaine</title>
            <description>5 ml once at end of surgery</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Bupivacaine HCl</title>
            <description>0.5%, 15 ml, once at end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Opioid Rescue Medication Use After Discharge From the PACU</title>
          <description>Pooled SABER-Bupivacaine parts 1 + 2 vs. Bupivacaine HCl</description>
          <population>mITT Population, results for only the prespecified analysis population {SABER-Bupivacaine (Part 1 and Part 2 combined) and Bupivacaine HCl (Part 2)} are provided, there was no prespecified secondary outcome measure that included the Saline Placebo (Part 1) arm or the SABER-Bupivacaine (Part 1) arm as a standalone treatment group.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="3.5" upper_limit="7.7"/>
                    <measurement group_id="O2" value="6.1" lower_limit="3.3" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PACU Discharge Eligibility as Assessed by Modified Post-Anesthesia Discharge Scoring System (mPADSS)</title>
        <description>mPADSS is a tool used to determine eligibility for discharge from the PACU after ambulatory surgery. It includes an assessment of parameters such as vital signs, activity level, nausea/vomiting, pain, and surgical bleeding. For this trial, evaluation of eligibility for PACU discharge by mPADSS has been slightly modified to provide a standardized means of assessing eligibility for PACU discharge across multiple investigative sites and also ensures that nonmedical complications, such as a missing ride home, do not interfere with evaluation of test drug effects.</description>
        <time_frame>From admission to discharge from PACU (Approximately 0 to 12 hours)</time_frame>
        <population>mITT Population, results for only the prespecified analysis population {SABER-Bupivacaine (Part 1 and Part 2 combined) and Bupivacaine HCl (Part 2)} are provided, there was no prespecified secondary outcome measure that included the Saline Placebo (Part 1) arm or the SABER-Bupivacaine (Part 1) arm as a standalone treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 and Part 2: SABER-Bupivacaine</title>
            <description>5 ml once at end of surgery</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Bupivacaine HCl</title>
            <description>0.5%, 15 ml, once at end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PACU Discharge Eligibility as Assessed by Modified Post-Anesthesia Discharge Scoring System (mPADSS)</title>
          <description>mPADSS is a tool used to determine eligibility for discharge from the PACU after ambulatory surgery. It includes an assessment of parameters such as vital signs, activity level, nausea/vomiting, pain, and surgical bleeding. For this trial, evaluation of eligibility for PACU discharge by mPADSS has been slightly modified to provide a standardized means of assessing eligibility for PACU discharge across multiple investigative sites and also ensures that nonmedical complications, such as a missing ride home, do not interfere with evaluation of test drug effects.</description>
          <population>mITT Population, results for only the prespecified analysis population {SABER-Bupivacaine (Part 1 and Part 2 combined) and Bupivacaine HCl (Part 2)} are provided, there was no prespecified secondary outcome measure that included the Saline Placebo (Part 1) arm or the SABER-Bupivacaine (Part 1) arm as a standalone treatment group.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.8" upper_limit="1.9"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.8" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 0-60 days after surgery (duration of time over which each participant was assessed).</time_frame>
      <desc>Systematic and Non-systematic reported TEAEs of &gt;5% (Safety Population)</desc>
      <group_list>
        <group group_id="E1">
          <title>SABER-Bupivacaine (Part 1)</title>
          <description>5 ml once at end of surgery</description>
        </group>
        <group group_id="E2">
          <title>Saline Placebo (Part 1)</title>
          <description>5 ml once at end of surgery</description>
        </group>
        <group group_id="E3">
          <title>SABER-Bupivacaine (Part 2)</title>
          <description>5 ml once at end of surgery</description>
        </group>
        <group group_id="E4">
          <title>Bupivacaine HCL (Part 2)</title>
          <description>0.5%, 15 ml, once at end of surgery</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="148" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="146" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation (Solicited)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Dysgeusia (Solicited)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Vomiting (Solicited)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incision site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Post procedural contusion</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="142" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="110" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Post procedural discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Dizziness (Solicited)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Headache (Solicited)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia (Solicited)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Nausea (solicited)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Paraesthesia (Solicited)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Somnolence (Solicited)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="65" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus (Solicited)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Deborah Scott</name_or_title>
      <organization>Durect Corporation</organization>
      <phone>408-777-1417</phone>
      <email>deborah.scott@durect.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

